High-dose intravenous phosphorus therapy for severe complicated hypophosphatemia

Area of Science:

• Nephrology
• Endocrinology
• Critical Care Medicine

Background:

• Severe hypophosphatemia (serum phosphorus ≤ 1 mg/dl) poses significant clinical risks.
• Multiple factors can contribute to severe hypophosphatemia, particularly in patients with normal renal function.
• Effective and safe intravenous phosphorus repletion strategies are crucial for managing this condition.

Purpose of the Study:

• To assess the efficacy and safety of a straightforward intravenous phosphorus repletion protocol.
• To evaluate the effectiveness of a specific phosphorus dosage and infusion schedule in correcting severe hypophosphatemia.
• To monitor serum electrolyte levels, including calcium, during treatment.

Main Methods:

• Prospective study involving ten adult patients with severe hypophosphatemia and normal renal function.
• Treatment involved intravenous infusion of 0.32 mmol phosphorus/kg body weight over 12 hours, repeated every 12 hours.
• Serum phosphorus, potassium, magnesium, and calcium levels were monitored at regular intervals.

Main Results:

• Serum phosphorus levels reached ≥ 2 mg/dl in all patients within 48 hours.
• Phosphorus levels normalized at 6, 12, 24, 36, and 48 hours in 1, 3, 3, 4, and 1 patient(s), respectively.
• No instances of dangerously low serum calcium levels were observed during the treatment period.

Conclusions:

• Intravenous administration of 0.32 mmol phosphorus/kg over 12 hours is an effective treatment for severe hypophosphatemia.
• This therapeutic approach is safe in patients with normal renal function and multiple causes of hypophosphatemia.
• The protocol demonstrates a favorable safety profile, with no significant adverse effects on serum calcium levels.